AESOP Technology focuses on AI-driven clinical decision support systems. The core team combines expertise in healthcare management, AI development, and international business expansion. The founders include a former hospital CIO and international product lead, spearheading the development of the Clinical Deep Inference Engine, now adopted by over 40 medical institutions. The Sales Director brings extensive experience in medical administration and consulting, leading B2B business development and international validation efforts. The team is committed to advancing Taiwan’s AI healthcare innovation onto the global stage.
AESOP’s core technology lies in its “Clinical Deep Inference Engine,” which integrates unsupervised machine learning algorithms, natural language processing (NLP), time-series analysis, and clinical knowledge graphs. The system extracts and analyzes heterogeneous medical data—including diagnoses, treatments, medications, lab reports, and patient demographics—from de-identified electronic medical records. Unlike traditional AI models that require large volumes of labeled data, this engine autonomously detects abnormal patterns to identify potential issues such as medication errors, missed diagnoses, redundant testing, and incorrect coding. Based on data relationships, it provides actionable suggestions to reduce medical errors and improve reimbursement efficiency.
The technology features a cross-modular architecture that covers semantic EMR analysis, clinical coding interpretation, care process logic, and billing calculation. It is suitable for healthcare institutions of all sizes. Built on a SaaS cloud-based infrastructure, the platform supports API integration and lightweight deployment. It also offers flexible pricing based on usage volume and is compliant with international standards (e.g., FHIR, HIPAA), making it highly scalable and globally applicable.
To date, the system has been implemented in over 40 hospitals and adopted by more than 5,000 clinical users. In 2024, two international pharmaceutical companies began using the system, validating its commercial viability and technical maturity. With continuous model optimization and data-driven feedback loops, AESOP is positioned to become a fundamental tool for clinical decision-making and medication safety in global healthcare.
- Clinical Deep Inference Engine
Utilizes unsupervised machine learning and anomaly detection to analyze multi-source data such as diagnoses, treatments, prescriptions, lab results, and patient characteristics. It proactively identifies risks such as medication errors, missed diagnoses, redundant tests, and coding anomalies, providing real-time corrective suggestions. - AI Clinical Decision Support System (AI-CDSS)
Provides real-time support to healthcare providers for medication safety, diagnostic accuracy, DRG/ICD code verification, and workflow optimization. It enhances patient safety, improves billing accuracy, and streamlines clinical operations. - Retrospective Data Analysis & Risk Assessment Reports
Performs simulation-based assessments using historical hospital data to generate hotspot maps, financial risk forecasts, and projected ROI. These reports assist in data-driven decision-making and serve as a pre-implementation evaluation tool. - SaaS Cloud Deployment & API Integration
Delivered via a scalable SaaS architecture with API connectivity to EMR/HIS systems. Flexible licensing options include usage-based or annual subscriptions, allowing for rapid implementation with minimal IT burden. To date, the platform has been adopted by over 40 hospitals and used by more than 5,000 physicians. It has also been piloted by two global pharmaceutical companies, demonstrating strong applicability across both clinical and pharmaceutical domains, and significant international expansion potential.
- Rapidly Growing Clinical Decision Support System (CDSS) Market
According to market research, the global CDSS market was valued at USD 3.12 billion in 2022 and is projected to grow to USD 6.9 billion by 2032, with a compound annual growth rate (CAGR) of 8.3%. The expansion of AI adoption and digital transformation in healthcare continues to drive demand. - Addressing High-Impact Pain Points: Medication Safety & Clinical Errors
Medical errors and adverse drug events remain a global concern. Hospitals urgently require AI tools that can autonomously detect and suggest corrections. AESOP’s platform, with its real-time detection and high accuracy, directly addresses needs in patient safety and financial risk management. - High Adaptability for Global Markets
The platform supports multilingual interfaces (Chinese and English) and integrates with global data standards such as ICD, DRG, and HL7/FHIR. Its modular design enables customization to fit the healthcare systems and reimbursement mechanisms of different countries, supporting global scalability. - Low Barrier to Adoption, Scalable Across Medical Institutions
With a SaaS and API-based licensing model, the system requires no additional hardware and is easily deployable in small to large-scale healthcare organizations. It can also be extended to pharmaceutical companies and insurance providers for collaborative data applications. - Data-Driven, Outcome-Oriented Marketing Strategy
AESOP employs a retrospective analysis model to engage clients, offering hospital-specific simulations and risk assessments before full deployment. This approach increases customer buy-in and has already led to successful implementations in over 40 hospitals, with contracts growing at a 3x annual rate. - Cross-Industry Applications: Pharma & Insurance Collaboration
Beyond hospitals, the platform holds strong potential in pharmaceutical post-market surveillance, insurance claims review, and health risk assessments, unlocking diverse revenue streams and long-term strategic partnerships.